Okay, here’s a revised version of the text, incorporating verification and corrections based on web searches as of today, January 26, 2026. I’ve focused on dates and the accuracy of the drug’s availability and FDA approval.
In late August 2024,Eisai and Biogen announced the availability of a subcutaneous formulation of lecanemab-irmb (LEQEMBI IQLIK™) allowing patients and caregivers to administer therapy at home,potentially reducing treatment time and the need for infusion centre visits.2 In its release, Eisai and Biogen stated that the subcutaneous administration may also decrease health care resource utilization associated with IV maintenance, including infusion planning and nurse monitoring, and increase capacity for new patients to initiate treatment and streamlining the overall AD care pathway.
In a recent interview, NeurologyLive® spoke with Robert Przybelski, MD, MS, a professor of geriatrics and gerontology at the University of Wisconsin and one of the first prescribers of the lecanemab-irmb autoinjector, to gain personal and clinical insights.Throughout the conversation, he emphasized the advantages of the self-administered autoinjector, particularly for patients who live in rural areas or those who travel seasonally. Even though the therapy is generally well-received and simplifies treatment administration, he noted that proper training might potentially be essential as of the complexity of the injection process. He also highlighted challenges with insurance coverage and expressed optimism about future treatment developments.
REFERENCES
1. Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous
Worth a look
Worth a look